1. Date of download: 6/24/2016 From: Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications Ann Intern Med. 2011;154(8):529-540. doi:10.7326/0003-4819-154-8-201104190-00004 Summary of evidence search and selection.CCTR = Cochrane Central Register of Controlled Trials; DARE = Database of Abstracts of Reviews of Effects; RCT = randomized, controlled trial; rFVIIa = recombinant factor VIIa. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2. Date of download: 6/24/2016 From: Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications Ann Intern Med. 2011;154(8):529-540. doi:10.7326/0003-4819-154-8-201104190-00004 Mortality and thomboembolic event risk differences (rFVIIa minus usual care) for indications with at least 2 comparative studies included in the effectiveness review.Indications with 2 or more comparative studies are included in the figure: ICH (30–33, 44), cardiac surgery (34, 35, 45–48), body trauma (36, 37, 49–51), brain trauma (38, 52), and liver transplantation (39–42, 53). Each circle represents a study. Larger circles correspond to larger studies, shaded circles represent studies on treatment use of rFVIIa, and open circles represent studies on prophylactic use of rFVIIa. Intracranial hemorrhage outcomes here reflect total TE events in contrast to the arterial TE events assessed in the meta-analyses. For cardiac surgery, 3 study circles overlap at the 0 abscissa for mortality risk, and 2 similarly overlap for TE event risk. ICH = intracranial hemorrhage; rFVIIa = recombinant factor VIIa; TE = thromboembolic. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3. Date of download: 6/24/2016 From: Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications Ann Intern Med. 2011;154(8):529-540. doi:10.7326/0003-4819-154-8-201104190-00004 Meta-analysis of mortality associated with off-label use of rFVIIa for ICH, adult cardiac surgery, and body trauma in RCTs and good-quality observational studies.For ICH, all studies are RCTs (30–33) and meta-analyses are done according to dosing category (low, medium, and high). For cardiac surgery, the studies by Diprose and colleagues (34) and Gill and coworkers (35) are RCTs, whereas those by Karkouti and colleagues (45) and Gelsomino and coworkers (46) are observational studies. For body trauma, all studies are RCTs (36, 37). ICH = intracranial hemorrhage; RCT = randomized, controlled trial; RD = risk difference; rFVIIa = recombinant factor VIIa. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

4. Date of download: 6/24/2016 From: Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications Ann Intern Med. 2011;154(8):529-540. doi:10.7326/0003-4819-154-8-201104190-00004 Meta-analysis of thromboembolic events and the acute respiratory distress syndrome associated with off-label use of rFVIIa for some indications in RCTs and good-quality observational studies.For ICH, all studies are RCTs (30–33), meta-analyses are done according to dosing category (low, medium, and high), and analyses of thromboembolic events are for arterial events only. For cardiac surgery, the studies by Diprose and colleagues (34) and Gill and coworkers (35) are RCTs, whereas those by Karkouti and colleagues (45) and Gelsomino and coworkers (46) are observational studies, and the meta-analyses of thromboembolic events evaluate all events (both arterial and venous). For body trauma, all studies are RCTs (36, 37), and the meta-analyses of thromboembolic events evaluate all events. ICH = intracranial hemorrhage; RCT = randomized, controlled trial; RD = risk difference; rFVIIa = recombinant factor VIIa. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

5. Date of download: 6/24/2016 From: Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications Ann Intern Med. 2011;154(8):529-540. doi:10.7326/0003-4819-154-8-201104190-00004 Harms analysis: weighted mortality and thromboembolic events in all RCTs and observational studies, by indication.Harms analyses include patients who received recombinant factor VIIa from registries and cohorts (noncomparative observational studies) with at least 15 patients (ICH [70–72], cardiac surgery [73–83], body trauma [84–87], brain trauma [88, 89], and liver transplantation [90, 91]), as well as patients from the treatment groups of all RCTs (30–43) and comparative observational studies (44–69), regardless of quality. For liver transplantation, the reported RCT rate of TE events is an underestimate, because 1 RCT (40) did not report venous events by group (treatment vs. placebo), so the events could not be tallied. For studies with overlapping data sets (e.g., the same registry patients being evaluated in a noncomparative study and a comparative observational study), the most complete data set for the outcome of interest was used. Comp Obs = comparative observational study; ICH = intracranial hemorrhage; Noncomp Obs = noncomparative observational study; RCT = randomized, controlled trial; TE = thromboembolic. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians